Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 156,783
  • Shares Outstanding, K 42,837
  • Annual Sales, $ 1,990 K
  • Annual Income, $ -59,980 K
  • 60-Month Beta 1.86
  • Price/Sales 78.36
  • Price/Cash Flow N/A
  • Price/Book 4.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.43
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.49 +10.60%
on 04/18/19
4.47 -13.65%
on 04/03/19
-0.08 (-2.03%)
since 03/22/19
3-Month
3.46 +11.56%
on 02/08/19
5.00 -22.80%
on 02/25/19
+0.27 (+7.52%)
since 01/23/19
52-Week
3.46 +11.56%
on 02/08/19
8.28 -53.38%
on 06/14/18
-2.52 (-39.50%)
since 04/23/18

Most Recent Stories

More News
Ocular Therapeutix(TM) Reports Changes to Board of Directors

Ocular Therapeutix, Inc.(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the...

OCUL : 3.86 (+5.46%)
New Research: Key Drivers of Growth for The Chemours, Superior Industries International, Caleres, G1 THERAPEUTICS, Vitamin Shoppe, and Ocular Therapeutix -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Chemours Company (NYSE:CC),...

CC : 39.77 (+1.09%)
GTHX : 19.49 (+5.24%)
VSI : 6.64 (+3.59%)
SUP : 5.88 (-1.34%)
CAL : 27.18 (+0.70%)
OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) to Present at the H.C. Wainwright Global Life Sciences Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the...

OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA(R) (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...

OCUL : 3.86 (+5.46%)
Recro Pharma Falls as FDA Denies Approval to Pain Candidate

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

AITB : 4.8500 (+1.04%)
ALKS : 34.23 (+1.66%)
REPH : 8.36 (+1.46%)
OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) Reports Election of Leslie Williams to Board of Directors

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...

OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) to Host 2019 Research & Development Day

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the...

OCUL : 3.86 (+5.46%)
Ocular Drug Delivery Technology Market Growing Demand and Trends 2019 to 2028

Ocular drug delivery technology is used in the treatment of ophthalmic diseases such as cataract, glaucoma, diabetic retinopathy etc. Manufactures are developing novel drug delivery technology which enables...

VRX.TO : 30.80 (-3.33%)
ALIM : 0.90 (-1.91%)
CLSD : 1.30 (+4.00%)
AGN : 142.17 (+1.36%)
NVS : 75.90 (+0.66%)
PFE : 39.42 (+1.13%)
OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) to Present at the Cowen and Company 39th Annual Health Care Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the...

OCUL : 3.86 (+5.46%)
Ocular Therapeutix(TM) To Report Fourth Quarter and Year End 2018 Financial Results

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...

OCUL : 3.86 (+5.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade OCUL with:

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

2nd Resistance Point 4.10
1st Resistance Point 3.98
Last Price 3.86
1st Support Level 3.68
2nd Support Level 3.49

See More

52-Week High 8.28
Fibonacci 61.8% 6.44
Fibonacci 50% 5.87
Fibonacci 38.2% 5.30
Last Price 3.86
52-Week Low 3.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar